Equities

Xinjiang Bai Hua Cun Pharma Tech Co Ltd

600721:SHH

Xinjiang Bai Hua Cun Pharma Tech Co Ltd

Actions
TechnologyTechnology
  • Price (CNY)5.69
  • Today's Change-0.06 / -1.04%
  • Shares traded9.30m
  • 1 Year change-22.90%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in CNYIncome statement in CNYView more

Year on year Xinjiang Bai Hua Cun Pharma Tech Co Ltd grew revenues 5.54% from 349.88m to 369.28m while net income improved from a loss of 34.75m to a gain of 12.97m.
Gross margin47.94%
Net profit margin5.68%
Operating margin6.88%
Return on assets2.12%
Return on equity3.19%
Return on investment2.99%
More ▼

Cash flow in CNYView more

In 2023, Xinjiang Bai Hua Cun Pharma Tech Co Ltd increased its cash reserves by 48.88%, or 66.34m. The company earned 62.08m from its operations for a Cash Flow Margin of 16.81%. In addition the company generated 19.91m cash from financing while 15.65m was spent on investing.
Cash flow per share--
Price/Cash flow per share--
Book value per share1.92
Tangible book value per share1.82
More ▼

Balance sheet in CNYView more

Xinjiang Bai Hua Cun Pharma Tech Co Ltd has a Debt to Total Capital ratio of 6.70%, a higher figure than the previous year's 0.25%.
Current ratio1.81
Quick ratio1.43
Total debt/total equity0.0719
Total debt/total capital0.067
More ▼

Growth rates in CNY

Year on year, growth in earnings per share excluding extraordinary items increased 136.97%.
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
169.62
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.